Ligand Pharmaceuticals Incorporated (FRA:LGDN)

Germany flag Germany · Delayed Price · Currency is EUR
161.00
-4.00 (-2.42%)
At close: Dec 4, 2025
41.23%
Market Cap 3.13B
Revenue (ttm) 214.13M
Net Income (ttm) 41.41M
Shares Out n/a
EPS (ttm) 2.12
PE Ratio 75.54
Forward PE 27.05
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume n/a
Open 164.00
Previous Close 165.00
Day's Range 161.00 - 164.00
52-Week Range 86.00 - 181.00
Beta n/a
RSI 37.25
Earnings Date Feb 11, 2026

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neurobla... [Read more]

Industry Pharmaceutical Preparations
Founded 1987
Employees 68
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol LGDN
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.